These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28894968)

  • 1. Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.
    Sato S; Li Y; Hattori N
    J Neural Transm (Vienna); 2017 Nov; 124(11):1395-1400. PubMed ID: 28894968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal impairment in Parkinson's disease.
    Dehay B; Martinez-Vicente M; Caldwell GA; Caldwell KA; Yue Z; Cookson MR; Klein C; Vila M; Bezard E
    Mov Disord; 2013 Jun; 28(6):725-32. PubMed ID: 23580333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice.
    Johnson ME; Bergkvist L; Stetzik L; Steiner JA; Meyerdirk L; Schulz E; Wolfrum E; Luk KC; Wesson DW; Krainc D; Brundin P
    Neurobiol Dis; 2021 Nov; 159():105513. PubMed ID: 34536552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson's disease.
    Dos Santos AV; Pestana CP; Diniz KR; Campos M; Abdalla-Carvalho CB; de Rosso AL; Pereira JS; Nicaretta DH; de Carvalho WL; Dos Santos JM; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2010 Nov; 485(2):121-4. PubMed ID: 20816920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
    Park JS; Blair NF; Sue CM
    Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Gaucher Disease Mutations in Parkinson Disease.
    Vilageliu L; Grinberg D
    Curr Protein Pept Sci; 2017; 18(7):758-764. PubMed ID: 26965692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal recessive mutations in the development of Parkinson's disease.
    Lopez G; Sidransky E
    Biomark Med; 2010 Oct; 4(5):713-21. PubMed ID: 20945983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H
    Fujii T; Nagamori S; Wiriyasermkul P; Zheng S; Yago A; Shimizu T; Tabuchi Y; Okumura T; Fujii T; Takeshima H; Sakai H
    Nat Commun; 2023 Apr; 14(1):2174. PubMed ID: 37080960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
    Park JS; Sue CM
    Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations.
    Kresojević N; Mijajlović M; Perić S; Pavlović A; Svetel M; Janković M; Dobričić V; Novaković I; Lakočević MB; Klein C; Kostić VS
    Parkinsonism Relat Disord; 2013 Apr; 19(4):431-5. PubMed ID: 23332636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
    Yang X; Xu Y
    Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease.
    Li Y; Sekine T; Funayama M; Li L; Yoshino H; Nishioka K; Tomiyama H; Hattori N
    Neurobiol Aging; 2014 Apr; 35(4):935.e3-8. PubMed ID: 24126159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of GBA for Parkinson's disease.
    Brockmann K; Berg D
    J Inherit Metab Dis; 2014 Jul; 37(4):643-8. PubMed ID: 24894157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease.
    Osellame LD; Rahim AA; Hargreaves IP; Gegg ME; Richard-Londt A; Brandner S; Waddington SN; Schapira AHV; Duchen MR
    Cell Metab; 2013 Jun; 17(6):941-953. PubMed ID: 23707074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
    Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
    Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.
    Shachar T; Lo Bianco C; Recchia A; Wiessner C; Raas-Rothschild A; Futerman AH
    Mov Disord; 2011 Aug; 26(9):1593-604. PubMed ID: 21618611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.